One key mechanism driving immunotherapy resistance involves the exclusion of cytotoxic T cells and NK cells from the tumor, due to the downregulation of important chemokines, such as CCL5, CXCL9, or CXCL1025–27. Here, CXCL9 is linked to neoplasm.